9.67

2.76% 0.26

After Hours: 9.67

Biocryst Pharmaceuticals Inc (BCRX)

Overview News Price History Option Chain Financials Why BCRX Down? Discussions Forecast

Biocryst Pharmaceuticals Inc stock is traded at $9.67, with a volume of 3.71M. It is up +2.76% in the last 24 hours and up +17.64% over the past month. BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Previous Close:

$9.41

Open:

$9.39

24h Volume:

3.71M

Relative Volume:

0.68

Market Cap:

$2.43B

Revenue:

$874.84M

Net Income/Loss:

$263.86M

P/E Ratio:

8.0376

EPS:

1.2031

Net Cash Flow:

$327.41M

1W Performance:

+0.83%

1M Performance:

+17.64%

6M Performance:

+50.62%

1Y Performance:

+37.36%

1-Day Range:

$9.37

$9.68

1-Week Range:

$9.34

$9.98

52-Week Range:

$6.00

$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name

Biocryst Pharmaceuticals Inc

Sector

Healthcare (1110)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

919-859-1302

Address

4505 EMPEROR BOULEVARD, DURHAM, NC

Employee

435

Twitter

@biocrystpharma

Next Earnings Date

2025-02-24

Latest SEC Filings

BCRX's Discussions on Twitter

Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCRX Biocryst Pharmaceuticals Inc	9.67	2.40B	874.84M	263.86M	327.41M	1.2031
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-18-26	Resumed	Evercore ISI	Outperform
Oct-15-25	Resumed	TD Cowen	Buy
Oct-01-25	Downgrade	Evercore ISI	Outperform → In-line
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Feb-25-25	Initiated	Wedbush	Outperform
Nov-20-23	Resumed	JP Morgan	Overweight
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-04-23	Upgrade	Jefferies	Hold → Buy
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy
Feb-22-23	Upgrade	Needham	Hold → Buy
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Dec-10-21	Initiated	Oppenheimer	Outperform
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight
Mar-01-21	Initiated	Cowen	Outperform
Sep-29-20	Resumed	JP Morgan	Overweight
Jun-17-20	Initiated	BTIG Research	Neutral
May-05-20	Upgrade	Barclays	Equal Weight → Overweight
Nov-15-19	Upgrade	BofA/Merrill	Neutral → Buy
May-24-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-16-18	Resumed	Piper Jaffray	Overweight
Aug-08-18	Resumed	JP Morgan	Overweight
Jul-17-18	Upgrade	BofA/Merrill	Underperform → Neutral
Jun-22-18	Initiated	Seaport Global Securities	Neutral
Jan-02-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Dec-20-17	Initiated	Barclays	Equal Weight
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Sep-06-17	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-17	Upgrade	Jefferies	Hold → Buy
Feb-16-17	Initiated	Ladenburg Thalmann	Buy
Aug-12-16	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-04-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	FBR Capital	Outperform
Feb-09-16	Downgrade	JP Morgan	Overweight → Neutral
Feb-09-16	Downgrade	Needham	Buy → Hold

View All

Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News

Apr 14, 2026

Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones - Stock Traders Daily

Apr 14, 2026

Apr 13, 2026

BioCryst to File Peramivir NDA Supported by BARDA/HHS Funding - AOL.com

Apr 13, 2026

BCRX Should I Buy - Intellectia AI

Apr 13, 2026

BCRX.O Forecast — Price Prediction for 2026. Should I Buy BCRX.O? - Intellectia AI

Apr 13, 2026

BCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 13, 2026

BCRX.O PE Ratio & Valuation, Is BCRX.O Overvalued - Intellectia AI

Apr 13, 2026

Apr 12, 2026

Free cash flow per share of BioCryst Pharmaceuticals, Inc. – DUS:BO1 - TradingView — Track All Markets

Apr 12, 2026

BCRX PE Ratio & Valuation, Is BCRX Overvalued - Intellectia AI

Apr 12, 2026

Apr 10, 2026

BCRX Stock Price, Quote & Chart | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill

Apr 10, 2026

A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment - Sahm

Apr 09, 2026

Apr 08, 2026

R&D Leadership Shake-Up at BioCryst (BCRX) Could Be A Game Changer For Its Pipeline Strategy - Sahm

Apr 08, 2026

Apr 07, 2026

BioCryst (BCRX) Chief R&D Officer receives large stock option and RSU inducement grants - Stock Titan

Apr 07, 2026

Sandeep Menon of BIOCRYST PHARMACEUTICALS (BCRX) submits Form 3 - Stock Titan

Apr 07, 2026

RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating - Moomoo

Apr 07, 2026

New Strong Buy Stocks for June 25th - MSN

Apr 07, 2026

BioCryst (BCRX) soars 13% on acquisition buzz - MSN

Apr 07, 2026